BioAge Labs rises on Novartis collaboration for age-related disease drugs

BioAge Labs

18/12/2024 15:19

** Drug developer BioAge Labs'  BIOA.O  shares rise ~10% to
$4.52
    ** BIOA says it is collaborating with Swiss drugmaker
Novartis  NOVN.S  to find new drug targets for age-related
diseases
    ** BIOA will receive $20 mln upfront and up to $530 mln in
milestone payments
    ** Including session's moves, stock down 80% YTD

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))